NOVARTIS

April 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2012-005102-22/ Novartis Protocol ID CQVA149A2328

A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD patients with moderate to severe airflow limitation

Trial CQVA149A2328 was cancelled with no patient enrollment and as such, no results will be reported.